Trials / Completed
CompletedNCT01470664
FST-100 in the Treatment of Acute Adenoviral Conjunctivitis
A Proof-of-Concept, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of FST-100 Ophthalmic Suspension in the Treatment of Acute Adenoviral Conjunctivitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 176 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This randomized, double masked, multi-center study is being conducted to support the safety and efficacy of FST-100 for the treatment of acute adenoviral conjunctivitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FST-100 | 0.1% dexamethasone and 0.6% polyvinylpyrrolidone iodine (PVP-Iodine) |
| DRUG | FST-100 (Component #1) | 0.6% PVP-Iodine ophthalmic solution alone |
| DRUG | FST-100 Vehicle | FST-100 Vehicle |
Timeline
- Start date
- 2012-12-17
- Primary completion
- 2014-05-23
- Completion
- 2014-05-23
- First posted
- 2011-11-11
- Last updated
- 2021-06-25
Locations
2 sites across 2 countries: United States, India
Source: ClinicalTrials.gov record NCT01470664. Inclusion in this directory is not an endorsement.